Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, explains the rationale for targeting novel antigens for CAR-T therapy in multiple myeloma, including activated integrin beta-7 and a glycoform of the CD98 heavy chain. This interview took place at the 38th World Congress of the International Society of Hematology 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.